Low vitamin D status has been associated with impaired glycemic control in patients with type 2 diabetes. The purpose of our study was to evaluate the effect of vitamin D supplementation on glycemic control in patients with type 2 diabetes.
Over the past decade, vitamin D has attracted substantial interest toward extraskeletal outcomes in various disease conditions, including diabetes (2, 3) . Vitamin D deficiency (defined as serum 25- (6, 7) . In addition, vitamin D is known to have immunomodulatory and anti-inflammatory effects and might reduce peripheral insulin resistance by altering low-grade chronic inflammation (8, 9) . Furthermore, insulin secretion and insulin sensitivity are both calciumdependent processes.
A large number of cross-sectional studies generally demonstrated an inverse association between vitamin D status and prevalence of hyperglycemia (4, 10) . Longitudinal studies have reported that low vitamin D status is a predictor for incident type 2 diabetes (11, 12) . Still, it remains unclear whether vitamin D deficiency and insulin resistance are causally related or whether they constitute two independent features of patients with type 2 diabetes. Results from previous intervention studies with vitamin D supplementation have been conflicting. A systematic review and meta-analysis of 15 studies examining the effect of vitamin D supplementation concluded that there is currently insufficient evidence of beneficial effect to recommend vitamin D supplementation as a means of improving glycemia or insulin resistance in patients with diabetes, impaired glucose tolerance, or normal fasting glucose (13) . A weak positive effect of vitamin D supplementation was seen on fasting glucose and insulin resistance in patients with type 2 diabetes. Inconsistency in these results may be due to the fact that many of the included reviewed studies used a different supplementation regimen, had a lack of power, did not have glycemic control as primary outcome, or did not include patients with type 2 diabetes.
Taken together, the causality of the association between vitamin D status and glycemic control in patients with type 2 diabetes has not yet been proven. We therefore designed this doubleblind, randomized, placebo-controlled trial to determine the effect of vitamin D supplementation on glycemic control in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS

Study Design and Participants
The SUNNY trial (acronym for the study on the effect of vitamin D supplementation on glycemic control in type 2 diabetes) is a double-blind, randomized, placebo-controlled clinical trial in which the effect of vitamin D supplementation on glycemic control was examined in patients with type 2 diabetes. A detailed description of the protocol can be found elsewhere (14) .
In brief, the trial was conducted in five general practices in and around Alkmaar, the Netherlands, at latitude 528. Adult patients ($18 years) with type 2 diabetes treated with lifestyle advice, metformin, or sulfonylurea (SU) derivatives, whether or not in combination, were invited by letter for participation in the study. Serum HbA 1c had to be stable and #8.0% (64 mmol/mol) for the last 3 months without recent changes in hypoglycemic agents. All patients were included between July 2012 and April 2013. This trial was approved by the Medical Ethics Committee of North Holland, the Netherlands, and was conducted according to the principles of the Declaration of Helsinki.
The main exclusion criteria were as follows: an impaired renal function (estimated glomerular filtration rate ,30 mL/min/1.73 m 2 , calculated from serum creatinine using the modification of renal disease formula), any granuloma forming disorder, hypercalcemia ( 
Intervention
All participants were randomized according to either an oral dose of cholecalciferol 50,000 IU once a month or an identically looking placebo 50,000 IU once a month for 6 months (Meander Medical Center, Amersfoort, the Netherlands). The patients were randomized 1:1 according to the method of block randomization with a block size of 10. No stratification was used. The randomization procedure was performed by the pharmacist. The participants and the research team remained blinded till the end of the study.
Outcome Measures
The primary outcome of the study was the change in serum HbA 1c between the vitamin D and placebo group after 6 months of intervention. Secondary outcomes were insulin resistance and b-cell function, measured through the HOMA of insulin resistance (HOMA-IR) and b-cell function (HOMA-B) 
Statistical Analysis
We calculated that 126 patients with type 2 diabetes would be required in this trial to demonstrate a significant difference at 80% power and 5% significance. Power calculations were based on the literature and aimed at a difference of 0.5% in HbA 1c value in the treated group as compared with the placebo group with an SD of 1.0% (15) . With an expected rate of 50% of the subjects having a serum 25(OH)D ,50 nmol/L, 252 subjects would be required to draw conclusions in vitamin D subgroups (deficient vs. sufficient). According to an expected drop out rate of 20%, 300 subjects were recruited.
All data were analyzed using the Statistical Package of the Social Sciences The efficacy analyses to explore the intervention effect on glycemic control were based on a modified intent-to-treat protocol, in which all randomized patients with at least one available postbaseline HbA 1c value were included. For patients with missing data at 6 months, the last measurement was carried forward. Perprotocol analysis was also performed including all patients who completed the trial. Linear regression analysis was used to assess the mean difference between intervention and placebo groups after 6 months (mean difference is reported as b). Change in HbA 1c was analyzed as primary outcome with randomization group and baseline values as explanatory measures. All effects were adjusted for baseline value, sex, season of measurement, baseline age and BMI, and ethnicity in line with earlier literature. For the prespecified subgroup analysis among patients with vitamin D deficiency and an HbA 1c level .7% (53 mmol/mol) at baseline, the same analyses were used. For the exploratory analysis among patients with a severe vitamin D deficiency, the results were solely adjusted for baseline value, age, and season of measurement, due to the small sample size with a lack of statistical power. Skewed continuous variables were natural log transformed before analysis. A two-sided P value ,0.05 was considered as statistically significant.
RESULTS
Of the 787 patients who were screened for eligibility, 423 were invited for participation. Of these, 300 potential participants were recruited for the study, of whom 275 showed up at the first visit and were randomized (139 and 136 in the placebo and vitamin D group, respectively). In total, 261 (95%) (132 in the placebo group and 129 in the vitamin D group) accomplished the 3 months measurement and were included in the intent-to-treat analysis (Fig. 1) . The main reasons for premature termination between start and completion of the trial were as follows: any alteration in oral hypoglycemic agents (n = 10), serum 25(OH)D ,15 or .150 nmol/L (n = 2), lost to follow-up (n = 10), and HbA 1c level .69 mmol/mol (8.5%) (n = 5). Baseline demographic, anthropometric, and biochemical characteristics of both groups are presented in Table 1 . The mean age of all patients was 67 6 8 years and 65% were male. The mean diabetes duration was 6 6 5 years with a mean baseline HbA 1c value of 6.8 6 0.5% (51 6 6 mmol/mmol). The antidiabetic treatment regimen did not differ between both groups. Overall mean serum 25(OH)D was 59. 8 (Table 2A) . Regarding mean change of the secondary outcomes, no significant differences between both groups were seen in other indicators of glycemic control (HOMA-IR, HOMA-B, fasting glucose, fasting insulin, and QUICKI) and anthropometric variables (Table 2A) . A significant difference, to the detriment of the vitamin D group, was observed in the total cholesterol-to-HDL ratio. This result, however, remained no longer significant after adjustment for the change in BMI over 6 months and baseline total cholesterol-to-HDL ratio (data not shown). Serum 25(OH)D and PTH significantly differed between both groups. Systolic blood pressure fell significantly in both groups (26.4 6 17.7 mmHg and P , 0.001 in the vitamin D group; 26.8 6 17.2 mmHg and P , 0.001 in the placebo group), but the difference between the intervention and control groups was not significant. Per protocol analysis did not change the results (data not shown).
Prespecified subgroup analysis in patients with a serum 25(OH)D ,50 nmol/L (n = 98) did not reveal any change in HbA 1c between both groups (b = 0.07 [95% CI 22.0 to 1.9]; P = 0.95) or in the other indicators of glycemic control (Table 2B ). In addition, no effect was seen in subgroups with reduced glycemic control (baseline HbA 1c .7.0% [53 mmol/mol]) (data not shown).
Performing an exploratory subgroup analysis in severe vitamin D-deficient patients (n = 19) demonstrated a significant mean difference of 3. (Table  2C ). In the safety profiles, one patient in the treatment group experienced new-onset urolithiasis who was excluded after 3 months. No other side effects were seen in the vitamin D group; in particular, none of the patients developed hypercalcemia during the study.
CONCLUSIONS
In this double-blind, placebo-controlled, randomized clinical trial, the effect of 6 months Our findings are consistent with a recent meta-analysis that reported that there is insufficient evidence of a beneficial effect to recommend vitamin D supplementation as a means of improving glycemic control in patients with type 2 diabetes (13) . Most studies that investigated the effect of vitamin D supplementation in patients with type 2 diabetes did not find a significant effect on glycemic control (20) (21) (22) (23) (24) . However, in one study performed by Nikooyeh et al. (25) in which patients were randomized into plain yogurt drink or vitamin D3-fortified yogurt drink (;1,000 IU/day), after 12 weeks, there was a significant reduction in HbA 1c , HOMA-IR, fasting insulin, and glucose.
Intervention studies among other study populations than type 2 diabetes yielded conflicting results (26) (27) (28) (29) . Possible reasons for the lack of an effect found in intervention studies might be related to the patient characteristics [e.g., baseline serum 25(OH)D and HbA 1c ], duration of the study, sample size, dosage or formulation of vitamin D supplement, and primary outcome of the studies.
The discrepancy between epidemiologic studies and intervention studies regarding vitamin D status is remarkable; almost all epidemiologic studies reported a significant association between vitamin D status and glycemic control or incident diabetes, whereas almost all intervention studies did not show an effect of vitamin D supplementation on glycemic indices. This observation suggests that vitamin D status could be more an expression of ill health rather than a cause of poor glycemic control.
Strengths of our study are the randomized, double-blind, placebo-controlled study design, the use of a large sample size with similar characteristics at baseline in the intervention and control groups, and the relatively high dose of vitamin D supplementation leading to adequate target levels of serum 25(OH)D.
Our study also has important limitations, which may partly be responsible for the lack of an effect found on glycemic control in the whole study population. First, our study population consisted of patients who were relatively well controlled in their diabetes regulation, treated with lifestyle advice whether or not in combination with oral hypoglycemic agents, with the majority of the patients having no cardiovascular complications. Moreover, only 37% of our included patients had a serum 25(OH)D ,50 nmol/L, instead of the estimated 50% to have enough power for a subgroup analysis of patients with a serum 25(OH)D ,50 nmol/L. It is imaginable that vitamin D supplementation is only effective in patients with vitamin D deficiency and that due to a power problem we did not find an effect on glycemic control in the subgroup with a serum 25(OH)D ,50 nmol/L (type II error).
Second, an important limitation is the use of a large intermittent dose of vitamin D supplementation, which is currently not promoted. Debate is ongoing whether vitamin D supplementation has to be given in a lower oral dosage once daily instead of a higher dose once a month (30) . We believe that another supplementation regimen would not have altered our results because the intervention group achieved a rise in serum 25(OH)D from 60.6 to 101.4 nmol/L, indicating an optimal increase. Another limitation of our study is the use of HOMA-IR to measure insulin resistance instead of hyperinsulinemic-euglycemic clamp, which is the gold standard method to assess insulin sensitivity.
In conclusion, a large intermittent dose of vitamin D supplementation at a level optimizing serum 25(OH)D did not improve glycemic control in patients with well-controlled type 2 diabetes. Further research among vitamin D-deficient patients with poorly regulated type 2 diabetes will be necessary to elucidate the question of whether vitamin D supplementation is effective on glycemic control or if it appears to be a marker of ill health.
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